Podcasts about Monty

 A fair amount of cutting back and pruning takes places at Longmeadow. Monty Don explains when it all happens and why, and clarifies when plants should be cut back and when to leave them. Along with making sure you have the correct tool for the job, he also discusses the importance of using the right gardening kit and techniques - and reassures that if mistakes are made, the plant will probably recover quicker than you think. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Sermon Notes Date: 08/31/2025 Preacher: Monty Simao, pastor Series: Zechariah Key Text: Zechariah 13:7-9 Description: What kind of love leads a Shepherd to take the sword? …even for sheep He knows will scatter? Today on Scandia Bible Church Podcast, Pastor Monty Simao continues in the book of Zechariah, where we see God summon the sword […]

Episode 573! It's AEW Forbidden Door! James, Jaxie, Monty and Gina are all here for all things AEW! We review the event and get a first hand account of being there! Plus lot's more! Enjoy!!

David, Kaiyah, Monty, Maor & Sheldon from The Engagement joins Seb live and in the studio to discuss all things to do with their new single ‘Closure’ ft. Kaiyah Mercedes lifted off their new 7-track EP ‘Shattered Illusion.’ They filmed a music video for it at the redwood forest, Warburton, and you can catch them performing ‘live’ supporting Malicy at Bergy Bandroom, Brunswick With over 1 million Spotify streams and a reputation for electrifying, high-energy performances, Melbourne’s alt-pop/rock band The Engagement are one of Australia’s most exciting rising acts. Their EP ‘Shattered Illusion’ is now available to listen/download on all streaming platforms everywhere. See omnystudio.com/listener for privacy information.

This week, Mel kicks us off with a truly excellent fact that blew our socks off, then we get into a bit of childhood nostalgia with a heavy Royal Melbourne Show theme. We also talk showering (together), baths, Monty tells us about her partner Sam's 'NSB' dinner and we have a cackle over some embarrassing for no reasons. Enjoy! Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here. See omnystudio.com/listener for privacy information.

Discover what goes on behind the TV scenes with Monty Don as he talks to Nicki Chapman at BBC Gardeners' World Live in June 2025. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode, Monty answers Listener Questions…tells you what it's like to have a kidney stone…and gives an update on the new Galactic Cowboys album. Plus…What's On TV?!

What a weekend! None of us have gotten as much sleep as we'd like with the Tour Championship on, but Tommy Fleetwood....what a star, and the entire golf world was celebrating his first win. Wonderful. Mark describes the final couple of holes as Tommy playing for his life, as he's not sure how another capitulation would have impacted him. As impressive as the win was, and as consistent as Tommy has been, Mark makes the point that - as with Jon Rahm and LIV last week, he doesn't believe that Tommy should be the Tour Champion, as Scheffler as 'without any shadow of a doubt' been the best player this year. Mark says both LIV and the PGA have this wrong. Nick and Mark discuss options to make it fairer.The new boss of the PGA has been talking about his plans, and one word in his comments has jumped out to Mark, he explains why and we discuss.The Ryder Cup selections will be this week for the US and Keegan Bradley has a big decision to make. Nick and Mark both have a view on what he should do, and explain why.This weekend Mark is playing Royal Melbourne, and he's hoping he is welcomed given his recent comments about the preparedness of the course for the Australian Open, however he is cheering for it to look incredible come December.Our new segment for BMW is a Touch of Class, and this week Nick O'Hern inducts Tommy Fleetwood as our inductee, not for his play, but for his press conference afterwards. We listen to what he said. It was indeed a touch of class from Tommy.Mark has bought something on Temu. Apologies. We tried to stop him but he was determined to show off this $3.50 purchase.After the turn Nick lists the Top 5 'Chokers' in golf......or does he? Top 5 for Betr, and as much as we loved Tommy winning he was responsible for our Betr multi failing so we're a bit dark on him at the same time.Lots of feedback for Southern Golf Club. Feedback on Rahm's title, some good news for Mark re: Monty, a whack for Nick and Mark from Billy, and a whack for Dan from Johnno. Brutal.Hardly know where to start with the PING global results, there has been some massive results - Tommy the big one, but an 'oh so close' result for Minjee in Canada, and plenty of other results to run through.And for watchMynumbers Marks masterclass today, inspired by Patrick Cantlay, is on the importance of having your weight in the right spot.We're live from Titleist and FootJoy HQ thanks to our great partners:Titleist, the #1 ball in golf;FootJoy, the #1 shoe and glove in golf;PING will help you play your best. See your local golf shop or professional for a PING club fitting;Golf Clearance Outlet, visit them online here to find your nearest store.Betr, the fastest and easiest betting app in Australia.And watchMynumbers: download from the App Store or Google Play, and Southern Golf Club: with their brand new Simulator Room. Hosted on Acast. See acast.com/privacy for more information.

Sermon Notes Date: 08/24/2025 Preacher: Monty Simao, pastor Series: Zechariah Key Text: Zechariah 13:1-6 Description: Grace. What if this very thing the Lord uses to forgive… is the same thing He uses to transform? Today on Scandia Bible Church Podcast, Pastor Monty Simao continues in our study of the book of Zechariah — where we […]

Episode 572! It's WWE Summerslam! James, Jaxie, Gina and Monty have so much WWE to catch up on! We have two nights of Summerslam! Raw and Smackdown notes! Plus lot's more! Enjoy!!

Monty sits down with the new head baseball coach for the Georgia Tech Yellow Jackets, James Ramsey!

Ralph, Monty and Desi get together to talk about the shambles that are Celtic at the moment.They ask "Just what the fuck is going on?" and try and find a few answers!They wonder "Are the fans the wean caught between 2 parents heading for a divorce?"Theres Fitbaw talk, Rants, Complaints and even some helpful suggestions through a packed 90 minutes!Maybe not one for  the Optimist CSC members mind!

Late summer bridges the lushness of summer and the early signs of autumn. Plants have grown and filled out, the borders are bursting and the garden is relaxed and full-grown. Monty Don discusses his flower borders at Longmeadow and how the Jewel Garden was created. Recorded live at BBC Gardeners' World Live in June. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Sumanta (Monty) Pal and Dr. Arielle Elkrief discuss the clinical relevance of the gut microbiome in cancer immunotherapy and the importance of antibiotic stewardship, as well as interventions currently being explored to treat gut dysbiosis and optimize immunotherapy response. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hi everyone, I'm Dr. Monty Pal, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist. I'm a professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  Today we're here to discuss one of my favorite topics, which is the gut microbiome. It's almost hard to avoid the gut microbiome nowadays if you look at medical literature within oncology. It's an emerging phenomenon, but there are a couple of individuals that I would really define as pioneers in the field. And one of them is actually with me today, Dr. Arielle Elkrief, to discuss the clinical relevance of the gut microbiome, particularly amongst patients receiving immunotherapy, although I imagine our conversation today will take many twists and turns. Arielle is an assistant professor and clinician scientist in the Department of Oncology at the University of Montreal, and she is co-director of the CHUM Microbiome Center there.  FYI for the listeners, we have our full disclosures in the transcript of this episode.  Arielle, thank you so much for joining us today. Dr. Arielle Elkrief: Thanks so much, Monty. This is going to be amazing. Dr. Sumanta (Monty) Pal: Well, I have to tell you what sort of inspired me to bring you on as a guest. It was one of many things, but it was this really terrific ASCO Educational [Book] article that you wrote. Now, I have to tell you, I've read all the articles sort of cover to cover in the book, and they're always a wonderful primer, so if our audience is studying for board research or something of that sort, it's a terrific resource to go through. I have to tell you, this piece on the gut microbiome that you wrote is nothing short of a masterpiece. If you read this cover to cover, it's actually going to give you, I think, a sense of the current state and future state of the field. I wanted to start by just sort of beginning with sort of the origin story for a lot of this, which is this association between the gut microbiome and immunotherapy response. This takes us back several years to this pivotal series of papers in Science. Maybe you could walk our audience through that. Dr. Arielle Elkrief: Absolutely. Well, thank you so much for your kind words about the ASCO [Educational] Book. It was a team effort with a lot of key opinion leaders in the field, so I'm really glad to learn that you've liked it.  Moving backwards in terms of how we came to understand that the gut microbiome is essential to priming a response to cancer immunotherapy actually goes back to 2015 and seminal papers that looked at what happens when we take mice that are germ-free mice that have never been exposed to a microbiome. These are mice that are born by cesarean section and essentially live in a bubble. And when we give those mice tumors and treat them, in the first papers with anti-CTLA-4 treatment, we realized that these antibodies don't work at all. And that was the first observation that the presence of a gut microbiome was essential to mounting an anti-cancer immune response. When we supplemented those same mice with beneficial bacteria or feces from responder patients, we were able to restore the response to immunotherapy. And so those were really the first preclinical observations that made us understand the critical role of the microbiome in immunotherapy response. Moving a little bit in the future, we examined the fecal microbiome composition using shotgun metagenomic sequencing in different cohorts of patients with solid tumors, namely lung cancers, kidney cancers, and also skin tumors like melanoma, and found that patients who responded to immunotherapy had a distinct microbiome that was characterized by beneficial bacteria compared to patients who experienced resistance to immunotherapy that had a dysbiotic or diseased microbiome. Dr. Sumanta (Monty) Pal: So, you know, it's interesting, these techniques that we're using to sequence the gut, they're a little bit different. So I wonder if you can give the audience a quick primer on these techniques that you're so well versed in, shotgun metagenomic sequencing, 16S rRNA sequencing. If you had to describe this in 30 seconds, which is a tall task, how would you do that? Dr. Arielle Elkrief: That's a tall task. Much of what we know about the microbiome initially came from a technique called 16S rRNA sequencing. This is a technique that amplifies the 16S region and basically tells you at the genus level what's going on at the level of bacterial composition. This technique is fast, relatively cheap, and can be performed on a laptop computer, which is excellent. The problem is that it's prone to a lot of technical variations. Different primers might give you different results, and you're really limited at the genus resolution. You can't get a good resolution in terms of species, and we're learning that different species from the same genus might have different physiological properties, and the same thing goes at the strain level. So when we really zone in and look at inter-species changes, we're seeing that these actually have specific functions in the host. So that brings us to metagenomic sequencing, which is a whole genome sequencing, next-generation sequencing based method that looks at the whole composition and gives you information not only on bacteria, but you might also get fungal and viral properties. You can zoom in on the strain level. You can also get functional output, so we can examine what the metabolic properties of specific species or strains might look like. The negative aspects of shotgun metagenomic sequencing is that it takes a lot of computational power in order to analyze the results and it might take a little bit longer. And certainly, within the clinical setting, not something that's feasible yet.  And that brings us to more novel point-of-care biomarker tools that we've collaborated in developing along with Dr. Laurence Zitvogel and Dr. Lisa Derosa at Gustave Roussy, that learning from the shotgun metagenomics results designed a probe using quantitative PCR which looks for this specific bacteria we know to be important and developed a ratio of harmful bacteria to beneficial bacteria. This is called the TOPOSCORE, and it actually is able to predict quite nicely the response to immunotherapy using a stool sample and a really good turnaround time of almost 72 hours. Dr. Sumanta (Monty) Pal: That was a perfect overview and a lot of information in a short amount of time. It also makes you take out your high school biology textbooks, doesn't it, to understand that the bacterial ribosome, right, is a different size and shape, and that's what we're sequencing here. But these techniques I think are incredibly important, and I'm glad you actually discussed this, this RT-PCR based strategy of calculating the TOPOSCORE. It lends itself to this phenomenon of dysbiosis, and I think for our audience, that's going to be an important term to understand as time goes on. There's the normal healthy gut and then there's this phenomenon of dysbiosis, which is, I guess, simply put, an unhealthy gut. But tell us about, you know, how often you see dysbiosis in a cancer patient, maybe versus a normal healthy adult. Dr. Arielle Elkrief: So, I think we can split up your question into two parts. One is we know from cohort studies and population level-based studies that the microbiome of patients with cancer is distinct from healthy patients or healthy people. And we know that because of the global composition. We also think that there are diversity metrics that lend themselves to being described as dysbiotic. But we do know that the microbiome of people with cancer is distinct from healthy volunteers. That's the first point.  In terms of how frequently dysbiosis occurs in patients with cancer, it's not very well defined. We know that even among healthy people, there is a certain level of dysbiosis. Laurence in her talk mentioned that to be about 10% to 20%. And the other fascinating component is that when we're thinking about dysbiosis and the cancer associated microbiome, in terms of the species that are enriched, it's quite striking that a lot of these dysbiotic or negative bacteria are also found to be enriched in patients with metabolic disease, like cardiovascular disease, for example. And so it's unclear if dysbiosis is the cause or consequence, but there definitely seems to be a general pattern of disease when looking at the microbiome compared to healthy people. Dr. Sumanta (Monty) Pal: That's interesting. So, I'll tell you, my second favorite portion of your article, and I'll tell you my favorite portion as well in the context of this podcast, but my second favorite part was the section around antibiotic stewardship. You know, the utilization of antibiotics in a very pragmatic fashion amongst our patients. Can you describe why that's so critical in the context of the microbiome? Dr. Arielle Elkrief: Antibiotics can disrupt the gut microbiome composition. We know this from mouse studies, but also cohort studies of patients that are exposed to antibiotics. And most importantly, we know that patients who are exposed to antibiotics, either before or during the immunotherapy period, have significantly worse progression-free survival and overall survival to immunotherapy. And this is true for immunotherapy in the monotherapy setting, but also when combined with chemotherapy. What's striking is that when we look at patients who are just treated with chemotherapy, we don't see the negative outcome of antibiotics on outcome and progression-free survival and overall survival, suggesting that the negative impact of antibiotics on outcomes is really specific to immunotherapy backbones. The other important point is that this negative signal is maintained even after adjusting for standard prognostic variables in the specific malignancies that we're looking at. And then most importantly, at the mechanistic level, we were able to actually pinpoint the mechanism behind this antibiotic related dysbiosis. And we see this with a bloom of negative bacteria which induces a loss of MAd-CAM, which is an endothelial gut checkpoint immune marker, and that causes an efflux of immunosuppressive T cells, which are usually in the gut, to go straight into the tumor where they make the tumor unamenable to an immunotherapy response. And so now we finally have the mechanism as to why antibiotics are harmful and why we need to practice antibiotic stewardship. Dr. Sumanta (Monty) Pal: And just to be clear for the audience, I mean, if a patient needs antibiotics, they need antibiotics. But perhaps it just suggests that, and we have, I suppose, this predilection as oncologists, just for the minor cold or cough or what have you, we maybe should be a little bit more cognizant of whether or not antibiotics are truly necessary. Is that fair? Dr. Arielle Elkrief: Absolutely. So what we're advocating for is antibiotic stewardship, and this is the clear recommendation that we can make. So that means confirming a bacterial infection. If it's there and antibiotics are indicated, to choose the most narrow spectrum for the shortest course and constantly re-evaluate the indication of antibiotics. And of course, we need to work with our colleagues in infectious diseases who've done incredible work in antibiotic stewardship. And all along this process we also need to be mindful of other medications and polypharmacy, such as proton pump inhibitors or narcotics, for example, we think that these other medications which are frequently prescribed in our cancer population can also potentially have negative impacts on the microbiome and immunotherapy response. Dr. Sumanta (Monty) Pal: I think that's a terrific summary and big guidance for the audience.  I promised you I'd tell you my favorite part of your article, and this is this huge table. I think the table is two and a half pages long, if I remember correctly, but it's an awesome table, and I highly recommend our audience to check this out. It lists literally every therapeutic trial for the microbiome under the sun. And so it begins with the approach of fecal microbiota transplant, which I'm going to ask you to tell us about in a second, but it also hinges on a lot of really cool sort of novel therapies, live bacterial products, mixes of different microbial products. Maybe take us through this whole approach of FMT (fecal microbiota transplantation). I actually wasn't aware of the dozens of trials that you listed there in this space. It seems like it's a very active area of research. Dr. Arielle Elkrief: Definitely. So, as you alluded to, FMT or fecal microbiota transplantation is the most well studied and direct way to modify the patient's microbiome. This technique aims to replace the patient's dysbiotic microbiome with that of a healthy microbiome, either from a healthy donor volunteer that's been heavily screened, or from a patient who experienced response to immunotherapy. And, as three landmark studies so far that have been published demonstrated the potential of FMT to reduce primary resistance or secondary resistance to immunotherapy, and this has been in melanoma.  We also recently reported on the results of our FMT-LUMINate trial, which looked at patients with lung cancer and melanoma. Once again, FMT, when combined with immunotherapy was safe and led to a higher proportion of responses than we would normally expect.  We're now also looking at randomized trials that have come out. So the first being the TACITO trial in kidney cancer, which compared FMT plus pembrolizumab and axitinib to placebo in patients with RCC, and again, FMT was safe and feasible and also led to an increased progression-free survival at one year, meeting the study's primary endpoint.  And so, so far, there's a wealth of data really showing the promise of FMT when combined with immunotherapy, and we're now in the process of conducting larger randomized trials, including in melanoma with the CCTG (Canada Cancer Trials Group) in our ME17 or Canbiome2 trial, where we're going to be enrolling 128 patients with metastatic melanoma to receive FMT and standard of care immunotherapy compared to standard of care immunotherapy alone. Dr. Sumanta (Monty) Pal: You're very humble, so I've got to highlight for our audience. This was a mega grant that Arielle received to fund really the largest prospective exploration of FMT that will exist to date. So I'm really excited about that. I wish this was something we could participate in stateside.  Before we jump into the other approach, which is live bacterial products and mixes thereof, where do you see FMT going? I think that one of the perceived challenges with FMT is that it's hard to implement, right? You need to have a really robust framework when it comes to gastroenterology, the preparation's challenging. Is there a way to envision FMT use being more generalized? Dr. Arielle Elkrief: Those are great questions. So we're lucky in Canada to work with pioneers in FMT, Michael Silverman, Saman Maleki, and John Lenehan in London, Ontario, who had this really robust FMT healthy donor screening program, which literally screens for every pathogen under the sun, and we haven't had any problems with feasibility or implementing FMT in Canada. But I think that once we're going to hopefully start doing larger scale, randomized phase three studies, that we might run into problems with scalability. And I think also with regards to reproducibility, and that's the feedback that we're getting from some regulatory authorities, especially at the level of the FDA, where there are some concerns around inter- and intra-donor variability because, of course, we can't guarantee that every fecal sample is going to be the same. So that has really pushed the field to think about other strategies, such as live biotherapeutic products which take modified FMT or bacteria from stools from either healthy donors or from responder patients and basically turn them into drugs that are regulated as drugs and can then be studied in the context of investigational new drugs or products. Dr. Sumanta (Monty) Pal: I like this and, you know, I do think that there's a future for it. We just have to kind of put our heads together and figure out how to get over all of these logistical hurdles, but, you know, I agree, I think your group and others have demonstrated, especially with this trial that you're fanning out all throughout Canada, that it can potentially be done.  This is a topic that could probably go on for another couple of hours, right, especially based on the size of the table that you put together in this brilliant article, but tell us about live bacterial products or LBPs, as we call them these days. What's the current status, what's the future there? And maybe I'll give you less than two minutes here, although again, I realize it's a two-hour topic. Dr. Arielle Elkrief: You're probably better suited to speak about that because you've been one of the pioneers in terms of this. So we can think about LBPs in terms of single strain organisms, like CBM588 for an example, which your group did some amazing work in showing that, in a randomized setting, that this led to better responses than we would expect compared to just work with controls. We also know that LBPs can have multiple strains, up to 30. We're collaborating with a company called Cannabis Bioscience that is actually working on much larger communities of consortia. And so we're really excited about the direction that that's taking in terms of taking these LBPs and developing them from the drug perspective. In addition to LBPs, we know that there are other ways that we can change the microbiome, notably prebiotics, which are compounds which can have a beneficial impact on the microbiome. And one of these is camu camu, which I know your group is leading a clinical trial looking at camu camu and kidney cancer, and we're excited to see how that compares to FMT or LBPs, because that might be a potentially scalable alternative. Dr. Sumanta (Monty) Pal: That's awesome. What a terrific overview, and that was less than two minutes. I don't know how you did it. That's terrific.  Arielle, this has been such an insightful conversation. I just want to thank you for, again, a terrific article in the ASCO Educational Book. I highly recommend all of our listeners to go there and check it out, and also for sharing all these terrific insights on the podcast today. Dr. Arielle Elkrief: Thank you so much, Monty. Dr. Sumanta (Monty) Pal: And thanks to our listeners, too. If you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal Dr. Arielle Elkrief Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Arielle Elkrief: Honoraria: AstraZenica, Bristol-Myers Squibb, Merck, EMD Serono Consulting or Advisory Role: Bristol-Myers Squibb Research Funding (Inst.): Kanvas Bioscience, AstraZeneca, Merck Other Relationship: Royal College of Surgeons and Physicians of Canada, Cedar's Cancer Center (Henry R. Shibata Fellowship), Canadian Institutes of Health Research (CIHR)

Episode 571! It's NXT Update! James and Monty are here for all things #WWENXT Plus we have #TNAEmergence #Triplemania and #NXTHeatwave Predictions!

FROM ABC NEWS to HIS SON'S OVERDOSE. Tommy Buddha and The Monty'man engage in a heartfelt conversation with Jeffrey Veach, who shares the profound impact of losing his son, Justin, to a drug overdose. They discuss the importance of real stories in recovery, the legacy of Justin's music, and the mission of the Justin Veach Fund, which provides scholarships to aspiring musicians. The conversation highlights the challenges of addiction, the role of music in healing, and the need for community support in addressing the drug crisis. Jeffrey's journey from tragedy to advocacy serves as an inspiration for others facing similar struggles. Closing Song: Can't Afford the Color by Justin Veatch www.facebook.com/Take12Radio www.tiktok.com/@take12radio www.instagram.com/take12radio  #recovery #alcoholic #twelvesteps #wedorecover #addiction 

This week, Mel kicks us off with an epic fact that even has Monty impressed. We chat about Taylor Swift’s album announcement, that time Lisa Bonet and Zoe Kravitz were the worst house guests ever, and Monty shares an intimate bit of info she has on a celeb you might not have thought of in a while. There’s also house renos, Paloma Faith, Jim Carrey’s real estate flop, Mel settles the Instagram debate of how many ‘several’ actually is, and a couple of gatecrashing family members clue Monty in on the meaning of the highly annoying 6’7. Fancy supporting us on Patreon? Find out more here. Follow us and get in touch on Instagram here. Follow us on Facebook here. See omnystudio.com/listener for privacy information.

Gerianne Pérez joins us for a candid and hilarious conversation about her winding path from choir kid to Broadway scene-stealer. She shares how an early love of a cappella shaped her artistry, why walking away from a “safe” office job was the best decision she ever made, and what it's like to audition for Six in front of a room full of other queens going for the same role. We get into her current adventure in Operation Mincemeat, where she covers multiple roles and leans into the joy—and chaos—of live theater, from botched hat tosses to full-on breaking on stage. Gerianne also opens up about navigating performance anxiety, the nuanced realities of being a Latina performer in a typecasting-heavy industry, and the thrill of telling a story that honors forgotten heroes of history. Whether she's singing backup for a fellow principal, leading the charge as Monty, or making the audience laugh through an unexpected mishap, Gerianne embodies resilience, humor, and heart at every turn. Gerianne Pérez is an NYU Tisch-trained actor and singer whose career spans Broadway, national tours, and acclaimed off-Broadway productions. She made her Broadway debut in In Transit before joining Waitress and the national tour of Six: The Musical. She has also appeared in In the Heights, Grease, and Oratorio for Living Things, and is currently bringing her comedic chops to Operation Mincemeat on Broadway. This episode is powered by WelcomeToTimesSquare.com, the billboard where you can be a star for a day. Connect with Gerianne: Instagram: @gerianne.perez TikTok: @gerianne.perez Connect with The Theatre Podcast: Support the podcast on Patreon and watch video versions of the episodes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/TheTheatrePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter & Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@theatre_podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook.com/OfficialTheatrePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TheTheatrePodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Alan's personal Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@alanseales⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email me at feedback@thetheatrepodcast.com. I want to know what you think. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 144 Quack quack quack, the boys are back! In this episode Scott gets his Summers/Grey history and power set mixed up, and then becomes obsessed with the concept of a new character. Meanwhile, Corwin still does not believe the TVA will show up in Doomsday, then gets hit with mid-2000s memories. The books for June and July of 2025 are reviewed and they say goodbye to the end of Ziglar's run…kinda. In Past-O-Vision they travel back to 2006 and pull the band aid off and finally review the Deadpool Arc in Ultimate Spider-Man. In Monty's predictions, they revisit their predictions from 8 months ago, and make some new ones. And what is this?! Juggerduck ends the show with a contest! 0:03:28 Superman and Fantastic Four Spoilers 0:30:14 Deadpool/Wolverine (2025) #6 0:37:13 Deadpool/Wolverine (2025) #7 0:43:31 Deadpool Kills the Marvel Universe One Last Time (2025) #3 0:55:10 Deadpool Kills the Marvel Universe One Last Time (2025) #4 1:02:07 Deadpool (2024) #350 1:18:14 Wolverines and Deadpools (2025) #1 Past-O-Vision1 1:34:32 Ultimate Spider-Man (2000) #91 1:48:41 Ultimate Spider-Man (2000) #92 1:56:39 Monty's Predictions   [MwaP RSS] Subscribe [RSS All] Subscribe [Google Podcasts] Subscribe [Apple Podcasts] Subscribe Music by Jenki Girls of Los Angeles Email: HipsterDaken@gmail.com Website: http://www.EarthsMightiestPodcast.comFacebook Group: https://www.facebook.com/MercWithaPodcast/ Episodes #1-26 can be found @ Cultural Wormhole.com The Merc Report has now joined the EMP family of podcasts and has now become The Merc With a Podcast! -EXPLICIT CONTENT

Sermon Notes Date: 08/17/2025 Preacher: Monty Simao, pastor Series: Zechariah Key Text: Zechariah 12:10-14 Description: “I will pour out on the house of David and on the inhabitants of Jerusalem the Spirit of grace and supplication, so that they will look on Me whom they have pierced; and they will mourn for Him as one […]

From printer demons haunting a rural church, to a customer swearing he needed an “Eee-whoa cable,” this episode is packed with hilarious Tales From Tech Support. We'll meet Monty, a manager who thought IT was there to set up his home internet, and a user who insisted their invoice printer was connected… when the cable was literally on the desk. And of course, we wrap up with a family dryer emergency that was solved in under a minute with a single button press.Check out Rob's 3D Prints Shop! https://Dangly3D.com

ADDICTION SONG COUNTDOWN RETURNS. The Montyman brings back the incredibly popular episode featuring the top 26 most requested Drug Addiction Awareness Songs of all time. Monty shares what you may not have known about songs that many people judged without investigating. Enjoy! www.facebook.com/Take12Radiowww.tiktok.com/@take12radiowww.instagram.com/take12radio #recovery #alcoholic #twelvesteps #wedorecover #addiction 

Ian Vandenberghe has a lifetime experience in a range of equestrianism, from Dressage to Stud Management & foal handling via Farriery. By 1991 he realised that he had an equal fascination for training people & added a teaching qualification to his CV. Ian has worked with Monty Roberts since 1993 and played a key part in the development of the first ever training courses in Monty's methods. Listen in... Horsemanship Radio 284:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Ian Vandenberghe has a lifetime experience in a range of equestrianism, from Dressage to Stud Management & foal handling via Farriery. By 1991 he realised that he had an equal fascination for training people & added a teaching qualification to his CV. Ian has worked with Monty Roberts since 1993 and played a key part in the development of the first ever training courses in Monty's methods. Listen in... Horsemanship Radio 284:Show Host: Debbie LoucksTitle Sponsor: HandsOn Gloves, All-In-One Shedding/Bathing/Grooming GlovesPhotos used with permissionLearn more about Good Horsemanship at Monty Roberts EQUUS Online University Monty's CalendarPlease follow Monty Roberts on FacebookFollow Monty Roberts on Twitter or on InstagramSee more at: MontyRoberts.comHear all the shows on the Horse Radio NetworkSupport the show

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content

Test Content